Pazdurcanumab: US FDA’s Top Cancer Official Weighs In On That Big Neurology Approval

Richard Pazdur is eager for a conversation about how to improve the Accelerated Approval pathway. The OCE director welcomes aducanumab’s approval – both on its own terms but also as an opportunity to broaden the discussion.

OCE Director Richard Pazdur is part of the US FDA's brain trust on accelerated approval • Source: photo illustration/Alamy, FDA

The US Food & Drug Administration’s top oncology review manager has a lot to say about the agency’s biggest neurological drug approval in decades.

During a 8 June interview with Prevision Policy’s Kate Rawson, Oncology Center of Excellence Director Richard Pazdur couldn’t wait...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards